Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of emraclidine in acute exacerbation of schizophrenia
2022-000581-17Phase 2Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emraclidine in schizophrenia (3 arms), sponsored by Cerevel Therapeutics. Primary endpoint: Change from baseline at Week 6 in PANSS total score. Started Aug 2022; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2022-000581-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000581-17.